Volume | 375,500 |
|
|||||
News | - | ||||||
Day High | 20.41 | Low High |
|||||
Day Low | 19.14 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Xencor Inc | XNCR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
19.27 | 19.14 | 20.41 | 19.98 | 19.23 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,723 | 375,500 | $ 20.00 | $ 7,511,172 | - | 16.49 - 28.96 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | formt | 1,200 | $ 19.98 | USD |
Xencor Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.22B | 61.12M | - | 168.34M | -126.09M | -2.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xencor News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XNCR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 18.88 | 20.41 | 17.945 | 18.64 | 616,065 | 1.10 | 5.83% |
1 Month | 22.23 | 22.23 | 17.945 | 20.02 | 547,334 | -2.25 | -10.12% |
3 Months | 18.72 | 26.84 | 17.945 | 22.02 | 703,239 | 1.26 | 6.73% |
6 Months | 17.65 | 26.84 | 16.49 | 20.96 | 628,924 | 2.33 | 13.20% |
1 Year | 27.94 | 28.96 | 16.49 | 21.82 | 473,681 | -7.96 | -28.49% |
3 Years | 44.11 | 44.80 | 16.49 | 26.84 | 362,810 | -24.13 | -54.70% |
5 Years | 31.15 | 58.345 | 16.49 | 30.87 | 360,495 | -11.17 | -35.86% |
Xencor Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. |